

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

Jens G. Lohr,^{1,2,10} Petar Stojanov,^{1,2,10} Scott L. Carter,^{1,10} Peter Cruz-Gordillo,¹ Michael S. Lawrence,¹ Daniel Auclair,¹ Carrie Sougnez,¹ Birgit Knoechel,^{1,2,3} Joshua Gould,¹ Gordon Saksena,¹ Kristian Cibulskis,¹ Aaron McKenna,¹ Michael A. Chapman,⁴ Ravid Straussman,¹ Joan Levy,⁵ Louise M. Perkins,⁵ Jonathan J. Keats,⁶ Steven E. Schumacher,^{1,2} Mara Rosenberg,¹ The Multiple Myeloma Research Consortium,¹¹ Gad Getz,^{1,7,12} and Todd R. Golub^{1,2,8,9,12,*}

¹Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02412, USA

²Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA

³Boston Children's Hospital, 350 Longwood Avenue, Boston, MA 02115, USA

⁴Cambridge Institute for Medical Research, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0XY, UK

⁵The Multiple Myeloma Research Foundation, 383 Main Avenue, Fifth Floor, Norwalk, CT 06581, USA

⁶Translational Genomics Research Institute (TGen), 445 N. Fifth Street, Phoenix, AZ 85004, USA

⁷Massachusetts General Hospital Cancer Center and Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA

⁸Harvard Medical School, Boston, MA 02115, USA

⁹Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA

¹⁰These authors contributed equally to this work

¹¹Participants who contributed patient samples to this effort are listed at the end of the manuscript

¹²These authors contributed equally to this work

*Correspondence: golub@broadinstitute.org

<http://dx.doi.org/10.1016/j.ccr.2013.12.015>

SUMMARY

We performed massively parallel sequencing of paired tumor/normal samples from 203 multiple myeloma (MM) patients and identified significantly mutated genes and copy number alterations and discovered putative tumor suppressor genes by determining homozygous deletions and loss of heterozygosity. We observed frequent mutations in *KRAS* (particularly in previously treated patients), *NRAS*, *BRAF*, *FAM46C*, *TP53*, and *DIS3* (particularly in nonhyperdiploid MM). Mutations were often present in subclonal populations, and multiple mutations within the same pathway (e.g., *KRAS*, *NRAS*, and *BRAF*) were observed in the same patient. In vitro modeling predicts only partial treatment efficacy of targeting subclonal mutations, and even growth promotion of nonmutated subclones in some cases. These results emphasize the importance of heterogeneity analysis for treatment decisions.

INTRODUCTION

We previously reported the sequencing of 38 matched tumor/normal multiple myeloma (MM) pairs, and that report of the genomic landscape of MM pointed to a number of recurrently mutated genes (e.g., *FAM46C* and *DIS3*) that are likely causal drivers of the disease (Chapman et al., 2011). However, that study design was only powered to detect commonly mutated genes, not less commonly mutated genes, due to the weak statistical power provided by the small sample size. It also did not

examine copy number alterations, leading to homozygous deletions or loss of heterozygosity (LOH), or clonal heterogeneity due to the modest sequence coverage (~30×) of those whole genome sequences.

The identification of driver mutations in MM holds great promise for personalized medicine, whereby patients with particular mutations would be treated with the appropriate targeted therapy (Fonseca et al., 2009; Mahindra et al., 2012; Palumbo and Anderson, 2011). However, if the mutation is present in only a fraction of the cells, one might doubt whether such targeted

Significance

A vision for precision cancer medicine calls for the deployment of molecularly targeted therapeutics in genetically defined patient populations. A first step in that process involves a description of the genetic landscape of cancer. We describe here a more comprehensive characterization of the MM genome, identifying recurrently mutated genes, copy number alterations, and signaling pathways. We find evidence for extensive clonal heterogeneity in the disease, a finding that may complicate the interpretation of genome-inspired clinical trials for MM. More generally, our findings indicate a need for the delineation of clonal heterogeneity in genome-based diagnostic approaches to cancer.

therapy would be clinically efficacious. Recent studies have documented the existence of clonal heterogeneity in solid tumors and acute myeloid leukemia, albeit in small numbers of patients (Campbell et al., 2010; Carter et al., 2012; Ding et al., 2012; Gerlinger et al., 2012; Nik-Zainal et al., 2012; Shah et al., 2012; Walter et al., 2012). These studies demonstrated how acquisition of genetic alterations over time leads to clonal evolution. Systemic treatment with chemotherapy may affect the fitness of some subclones more than others, and thus may alter the tumor composition by promoting particular subclones (Landau et al., 2013b). Consequently, the full breadth of tumor heterogeneity, particularly in solid malignancies, may not be captured in a single biopsy, which represents a challenge for cancer therapy (Gerlinger et al., 2012). Clonal heterogeneity and clonal evolution have also been observed in MM by either whole-exome sequencing or array comparative genomic hybridization (CGH), albeit in a modest number of patients (Egan et al., 2012; Keats et al., 2012; Walker et al., 2012).

We therefore sought to estimate the extent of clonal heterogeneity in MM in a large-scale MM genome sequencing data set capturing a breadth of untreated and previously treated patients and to infer the timing of genetic events in MM. In the work presented here, we address several important questions: (1) can we identify significantly mutated genes by integrating evidence from both point mutations and copy number analysis, (2) how do the mutation profile and the clonal and subclonal composition of MM differ between hyperdiploid and nonhyperdiploid and between treated and untreated MM, and (3) can the contribution of subclones in a patient be reconstructed from a single biopsy to inform targeted therapy?

RESULTS

We first set out to create a MM genome data set that would be sufficiently powered to comprehensively assess the genetic diversity of the disease and the extent to which subclonal heterogeneity is observed within patients. Approval for this study was obtained as outlined in the [Experimental Procedures](#), and a total of 203 tumor-normal pairs were analyzed: 177 by whole-exome sequencing and 26 by whole-genome sequencing (16 and 23, respectively, have been previously reported [Chapman et al., 2011]). The average depth of coverage for the whole exomes and whole genomes was 89× and 30×, respectively. To estimate the statistical significance of mutation frequency (as a measure of positive selection), we used a new version of the MutSig algorithm (MutSigCV) that compares observed mutation frequencies against sequence context-specific, tumor-specific, and gene-specific background mutation frequencies (Lawrence et al., 2013). Additionally, we developed analytical tools to further prioritize homozygous somatic single-nucleotide variants (SSNVs), or genes which harbor mutations that are positionally clustered or preferentially affecting highly conserved amino acids (see the [Supplemental Experimental Procedures](#) available online). Analysis of the 203 tumor-normal pairs showed that 11 genes were recurrently mutated using a standard significance threshold of $q < 0.1$ (Figures 1 and S1). The individual and combined p and q values for these prioritization procedures are shown in [Tables S1](#) and [S2](#). Mutation validation studies were performed on 140 mutations, with a validation rate of

90.4%, in line with other large-scale cancer genome sequencing studies ([Table S2](#)).

Among the 11 significantly mutated genes were five genes (*KRAS*, *NRAS*, *FAM46C*, *DIS3*, and *TP53*) previously identified as the most commonly mutated genes in our 38-patient pilot MM genome study (Chapman et al., 2011). An additional four genes (*BRAF*, *TRAF3*, *CYLD*, and *RB1*) have been implicated in the pathogenesis of MM (Annunziata et al., 2007; Chapman et al., 2011; Demchenko et al., 2010; Keats et al., 2007; Walker et al., 2012). *PRDM1* is a transcriptional repressor that is involved in plasmacytic differentiation, and it acts as a tumor suppressor gene in activated B cell-like diffuse large B cell lymphoma (DLBCL). Mutations that disrupt its function have been described in DLBCL (Mandelbaum et al., 2010), but are not known to play a role in MM. *PRDM1* has been shown to promote survival of transformed plasma cells (Lin et al., 2007), and transgenic mice prone to plasmacytoma development show reduced plasmacytoma incidence if one or two *PRDM1* alleles are knocked out (D'Costa et al., 2009). We find a recurrent missense mutation (S552C) in two patients, with two additional patients harboring closely clustered missense mutations (S605R and S606I), and an additional five patients with truncating frame shift or splice site mutations, supporting a role of *PRDM1* as a tumor suppressor (Figures 1 and S1; [Tables S1](#) and [S2](#)).

Additionally, several recurrently mutated and biologically relevant genes fall just below the significance threshold ([Table S1](#)). For example, *EGR1* was previously shown to abrogate JUN-induced MM growth inhibition and cell death when knocked down in MM cells and has been reported as a mechanism of resistance to MM therapy (Chen et al., 2010). We found that *EGR1* mutations were clustered toward the 5' end of the gene ([Tables S1](#) and [S2](#); [Figure S1](#)), a pattern of mutation often associated with somatic hypermutation (Pasqualucci et al., 2001). To further explore this possibility, we asked whether the observed mutations occurred within WRCY motifs known to be the targets of activation-induced cytidine deaminase (AID), a key enzyme that catalyzes somatic hypermutation. This analysis revealed that *EGR1* indeed had significant enrichment of mutations in WRCY motifs ($q < 0.1$; [Table S3](#)), consistent with a somatic hypermutation mechanism. Whether these mutations act as “drivers” and are positively selected or merely constitute “passengers” remains to be seen.

We also found four missense mutations in the interferon regulatory factor *IRF4*, with three of the mutations being identical (K123R) (Chapman et al., 2011), establishing K123R as a recurrent, “hot spot” mutation in *IRF4* ([Figure S1](#); [Table S2](#)). *IRF4* has previously been reported as a MM survival factor, wherein a loss-of-function RNAi screen showed that *IRF4* inhibition results in loss of viability of MM cell lines (Shaffer et al., 2008). *SP140* is the lymphoid-restricted homolog of *SP100*, expressed in plasma cells, and a genome-wide association study identified *SP140* as a susceptibility locus for chronic lymphocytic leukemia (Di Bernardo et al., 2008), with risk alleles being associated with reduced levels of *SP140* mRNA. We identified missense, nonsense, frame shift, and splice site alterations in eight patients, with LOH observed for two of these alterations, consistent with its possible role as a tumor suppressor in MM.

The available clinical characteristics of the patients in the study are shown in [Figure 2](#) and [Table S4](#). Identification of




Figure 1. Determining Significantly Mutated Genes in 203 Patients with MM

(A) The rate of synonymous and nonsynonymous mutations is displayed as mutations per megabase (of exome), with individual MM samples ranked by total number of mutations.

(B) The heatmap represents individual mutations in 203 patient samples, color-coded by type of mutation. Only one mutation per gene is shown if multiple mutations were found in a sample. Left: the histogram shows the number of mutations in each gene. Percentages represent the fraction of tumors with at least one mutation in the specified gene. Right: the 11 genes with the lowest q value (q combined in Table S1), ranked by level of significance, are shown.

(C) Base substitution and allelic fraction distribution of individual samples, ranked in the same order as in (A).


See also Figure S1 and Tables S1, S2, and S3.

significantly mutated genes exclusively in patients with t(4;14) and t(11;14), as obtained for 50 patients subjected to routine clinical fluorescence in situ hybridization (FISH) testing, did not reveal additional significantly mutated genes (Table S1). In general, there was no strong statistically significant association between particular mutations and clinical features, tumor ploidy, or history of prior treatment, but hypothesis-generating trends could be observed (Figure 2; Tables S1 and S5). The sample size might need to be larger to definitively address such associations.

Tumor suppressor genes can be inactivated not only by point mutation, but also by biallelic deletion. We therefore searched for genes with a statistically significant excess of homozygous deletion (using a modification of the GISTIC algorithm [Beroukhi et al., 2007; Mermel et al., 2011]) across the 153 patients in our study for whom high-density copy number array data were available. Deletions were identified as being homozygous using the ABSOLUTE algorithm [Carter et al., 2012]. We identified seven significant regions, containing 32 genes, including known tumor suppressor genes such as *CDKN2C*, as well as genes associated with the regulation of the NF- κ B signaling pathway, including *TRAF3*, *BIRC2*, *BIRC3*, and *CYLD* (Figure 2; Table S6). *CYLD* was also found to be significantly mutated in five patients (Figures 1 and 2), and its inactivation through deletions and mutations has been described in MM (Demchenko et al., 2010; Keats et al., 2007). Similarly, the exonuclease-encoding *DIS3* gene is subject to point mutations with LOH (as determined

by ABSOLUTE [Carter et al., 2012]), strongly implicating *DIS3* as a tumor suppressor in 11% of MM patients (Figure 2). In order to designate samples as either hyperdiploid or nonhyperdiploid with high resolution, we developed and validated a classification method using WES and WGS (Figure S2A; Supplemental Experimental Procedures). Interestingly, *DIS3* aberration was more commonly seen among the 86 nonhyperdiploid MM cases compared to the 116 hyperdiploid cases (Fisher's exact test, $p = 0.00013$; Table S5), with a nonsignificant trend toward a greater fraction of LOH in *DIS3*-mutated nonhyperdiploid patients compared to hyperdiploid samples (Fisher's exact test, $p = 0.13$). We also found an excess of homozygous deletions in the gene encoding the tyrosine phosphatase *PTPRD*, which has recently been implicated as a tumor suppressor in MM, glioblastoma, and other cancers (Kamada et al., 2012). *PTPRD* dephosphorylates STAT3, which promotes signaling from interleukin-6, a well-recognized MM survival factor. Whether interleukin-6 signaling is indeed the mechanistic target of *PTPRD* deletion remains to be established. We also found homozygous deletions with a peak at 8p23.1 (with 18 genes) containing several candidate tumor suppressor genes (*BLK*, *MSRA*, *PINX1*, and *SOX7*) for which a connection to MM has not been previously established.

We next asked whether there was evidence to support pathway-level patterns of mutation, whereby mutations in individual genes may lack statistical significance but when multiple members of a pathway or functionally related gene set are






Figure 3. Clonal Heterogeneity of Significantly Mutated Genes in MM

(A) The numbers of predicted subclones by clustering of cancer cell fractions are shown, as described in the [Supplemental Experimental Procedures](#). As a comparison, the predicted distribution of the number of subclones is also shown for a cohort of patients with ovarian cancer. Error bars represent the SD.

(B) The CCF, i.e., the expected fraction of MM cells that harbor a coding mutation in the indicated gene, is shown. Each symbol represents a somatic mutation in an individual patient. The most significantly mutated genes are shown. On the basis of the probability distribution, mutations were determined to be either clonal (red circles, upper bound of CCF confidence interval ≥ 0.95) or subclonal (blue circles, upper bound of CCF confidence interval < 0.95). Error bars represent the 95% confidence interval.

(C) Co-occurrence of significant mutations in the same patient is depicted. Results of the Bayesian clustering procedure were applied to SSVN CCF distributions for *KRAS*, *NRAS*, and *BRAF* in samples that harbor mutations in at least two of these three oncogenes. Probability distributions over CCF for the co-occurring SSVN in the indicated oncogenes before clustering (black curves) and after clustering (filled red bars) are shown.

(D) The fraction of somatic mutations that are present at the indicated CCF are shown for the 11 most significantly mutated genes. Mutations in significantly mutated genes occur at significantly higher CCFs in previously treated patients compared to untreated patients ($p = 0.007$, Wilcoxon rank-sum test).

See also [Figure S3](#).

mutated (albeit rarely), significance is observed. We first tested the three gene set hypotheses that emerged from a pilot analysis of the MM genome, namely the NF- κ B pathway, histone-modifying enzymes, and the coagulation cascade ([Chapman et al., 2011](#)). Indeed, we find that all three gene sets retain statistical significance across our collection of 203 patients ($p < 0.05$), if tested as individual hypotheses ([Table S7](#)). Next, we tested a collection of 612 curated gene sets (taken from MSigDB [[Subramanian et al., 2005](#)]) and found that six gene sets reached statis-

tical significance after correction for multiple-hypothesis testing ([Table S7](#)). These gene sets primarily include mutated components of the cell-cycle machinery (including CDKN1B and CCND1) and serve to highlight genes that are only borderline significant when analyzed individually, but reach significance as part of these gene sets. For example, we observed three coding mutations (accompanied by LOH) in the transcription factor MAX, as part of a significantly mutated gene set, which functions as a heterodimerization partner for MYC, which is well known to

be dysregulated in MM (Shou et al., 2000). Interestingly, *MAX* has been implicated as a tumor suppressor susceptibility gene in pheochromocytoma (Comino-Méndez et al., 2011), and a small-molecule inhibitor of MYC-MAX heterodimerization has been reported to result in myeloma cell death (Holien et al., 2012).

Of the 203 patients in the study, 131 (65%) had evidence of mutations in one or more of the 11 recurrently mutated genes, and 103 (51%) had mutations of a gene within a statistically significant gene set (new and previously published in Table S8, excluding significantly mutated genes), accounting for a total of 166 patients (82%). Of the remaining 18% of tumors lacking such obviously functionally important mutations, some are likely to be driven by rare mutations in bona fide driver genes (e.g., the tumors with mutations in *MYD88* or *CARD11*, previously reported to be recurrently mutated in the B cell malignancy DLBCL [Lohr et al., 2012; Morin et al., 2011]; Tables S1 and S2). Tumors lacking such mutations might alternatively be driven by focal copy number alterations or chromosomal rearrangements. Of the 153 patients from whom copy number array data were available, 119 patients (including 40 of the 60 patients lacking SSNV in the most significantly mutated genes) had evidence of at least one focal gene copy number gain or loss within a significant peak (Figures 2 and S2B; Table S8). Twenty-one patients (of 139 patients with high-density copy number array and ABSOLUTE data) harbored homozygous deletions in significant peaks (Figure 2). Similarly, structural variants were found in all of the 26 patients from whom whole-genome sequencing was available (Chapman et al., 2011), including three previously unpublished patients (Table S9). Whether such gene rearrangements are indeed causal of MM in these patients remains to be proven.

We next addressed the extent to which clonal heterogeneity exists in MM. To do this, we computed the allelic fraction of each SSNV. The allelic fraction estimation alone (Figure 1), however, cannot be used to assess the fraction of cancer cells harboring the mutation because it does not take into account (1) the copy number at that locus or (2) tumor purity (whereby normal cell contamination can lead to the spurious impression of mutation subclonality). We therefore used the ABSOLUTE algorithm (Carter et al., 2012) to estimate the cancer cell fraction (CCF) of each SSNV by modeling the observed wild-type and mutated allele counts, taking into account local somatic copy number and sample purity, calculated from high-density SNP array or sequencing data (Figure S3) (Landau et al., 2013a). The CCF estimates for all SSNVs in a given sample were then analyzed with a Bayesian clustering algorithm (Landau et al., 2013b) to estimate the number of subclonal cell populations present in each tumor (Figure S3; Experimental Procedures).

Looking across the entire coding region, we found that samples with a purity greater than 0.7, nearly all had evidence of clonal heterogeneity (Figure 3A). Most patients harbored at least three detectable subclones (beyond the major clone), with some patients having as many as seven. For comparison, the same analysis applied to ovarian cancer (Cancer Genome Atlas Research Network, 2011) (sequenced to similar depth and with similar purities) showed that a lower proportion of MM patients (8%) had one or no subclones compared to ovarian cancer (19%; Fisher's exact test, $p = 0.0047$; Figure 3A).

We next asked whether certain types of mutations tend to be clonal (consistent with early events) whereas others might tend to be subclonal (consistent with later events). It was conceivable that true driver mutations (e.g., those reaching statistical significance based on mutation frequency or those with strong connections to MM biology) might be exclusively clonal events. This, however, was not the case. Mutations in most of these genes were found to be clonal in some patients and subclonal in others, including some cases with subclonal coding mutations occurring on segments with subclonal copy number change (Figure 3B; Table S2). For example, of the 44 coding *KRAS* mutations that were analyzed for clonality, 32 (73%) were clonal, whereas for 12 (27%) were subclonal, detectable in as few as 13% of cells in some patients.

In some cases, we observed multiple significant mutations in the same tumor sample, including mutations in oncogenes whose function might be expected to be redundant. For example, some patients had mutations in two of three oncogenes (*NRAS*, *BRAF*, and *KRAS*) (Figure 3C), or two mutations in *KRAS* (Table S2), despite the fact that these mutations similarly activate the MAP kinase pathway and therefore seemed unlikely to occur in the same tumor. We therefore asked whether there was evidence to support these mutations being present in the same clones, or rather in different subclones within the tumor. We reasoned that if they occurred in the same cell, we should find some cases in which both mutations were clonal. This analysis indicated that, consistent with their biological function, *KRAS*, *NRAS*, and *BRAF* mutations were rarely simultaneously clonal in our patient samples (one sample); instead, they were mostly either both subclonal within the tumor or they occurred in a nested fashion (i.e., one clone being the subclone of another; nine samples). While these data indicate that mutations in *KRAS*, *NRAS*, and *BRAF* can coexist in the same cell, such subclones often did not appear to have sufficient selective advantage to grow to clonality. In contrast, we found that *DIS3* and *KRAS* mutations were often simultaneously clonal (Table S2). *DIS3* is known to encode a ribonuclease involved in RNA processing, but how loss-of-function *DIS3* mutations are oncogenic and how they interact with *KRAS* in cellular transformation remain to be determined. Interestingly, we found that in general, significantly recurrent mutations were more often clonal in previously treated compared to untreated patients and occurred at higher CCFs ($p = 0.007$, Wilcoxon rank-sum test) (Figure 3D). This suggests that treatment might accelerate the fixation of certain subclones by eliminating less fit clones.

We next explored the therapeutic implications of the observed clonal heterogeneity. Specifically, we focused on *BRAF*, because the observation of *BRAF* activating mutations in MM has stimulated clinical exploration of *BRAF* inhibitors in this disease. Indeed, a recent report of a single *BRAF*-mutant MM patient showing durable response to a *BRAF* inhibitor is encouraging (Andrulis et al., 2013). Consistent with that clinical response, we found that U266 cells, which express the *BRAF*-K601N mutant (COSMIC database, <http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/>) that has been shown to cause elevated phospho-MEK and phospho-ERK levels in other malignancies (Dahlman et al., 2012), were more sensitive to treatment with the *BRAF* inhibitor PLX4720 compared to *BRAF*-wild-type cell lines (Figure 4A and 4B). In addition, *BRAF* inhibition




Figure 4. Heterogeneity Composition Determines the Response to Targeted Therapy

(A) The *BRAF*-wild-type MM cell lines OPM2 (*NRAS* and *KRAS* WT, *FGFR3* K650E), MM1S (*KRAS* G12A), and SKMM1 (*NRAS* G12D) and the *BRAF*-mutant MM cell line U266 (*BRAF* K601N) were treated with the *BRAF* inhibitor PLX4720 at the indicated concentrations. Phosphorylated and total MEK and ERK were detected by western blot at the indicated time points.

(B) The indicated cell lines were cultured for 5 days in the absence or presence of increasing concentrations of the *BRAF* inhibitor dabrafenib. Cell numbers were determined by flow cytometry on day 5 of culture and normalized to the cell number at a dabrafenib concentration of 0 μ M (100%). Error bars represent the SD.

(C) The indicated MM cell lines were cultured in the presence of the MEK inhibitor trametinib with or without dabrafenib at varying doses. The cell number on day 5 of culture was determined by cell titer glo. Curves with darker shades of gray represent higher concentrations of dabrafenib.

downregulated MAP kinase pathway activity only in *BRAF*-mutant MM cells, whereas in *BRAF*-wild-type cells, the pathway was paradoxically upregulated (Figure 4A), similar to reports in melanoma (Poulidakos et al., 2010). Strikingly, paradoxical pathway activation was even more pronounced in the presence of *KRAS* or *NRAS* mutations, and this increased MAP kinase activity was associated with *BRAF*-inhibitor-induced growth stimulation of *KRAS*- or *NRAS*-mutant MM cell lines (Figure 4B). Taken

together, these results suggest that treatment of patients harboring subclonal *BRAF* mutations may at best have only partial responses when treated with *BRAF* inhibitors.

The presence of MAP kinase pathway activation in MM has similarly increased interest in the clinical testing of MEK inhibitors in MM (Annunziata et al., 2011; Tai et al., 2007). In melanoma, the combination of MEK and *BRAF* inhibitors appears to be efficacious with a favorable toxicity profile, and the

combination appears to abrogate the paradoxical activation of the MAP kinase pathway in *BRAF*-wild-type cells (Flaherty et al., 2012). In MM cell lines, we found that combination treatment resulted in increased killing of *BRAF*-mutant cells, whereas a combination benefit was not observed in *BRAF*-wild-type cell lines (Figure 4C). These results support the clinical exploration of combination *BRAF*/MEK inhibitors in clonal, *BRAF*-mutant MM.

DISCUSSION

The modern oncology paradigm holds that the characterization of tumor genomes will reveal a coherent view of the pathogenesis of cancer and that this in turn will lead to the development of targeted therapies. Our characterization of 203 MM genomes represents by far the most comprehensive effort reported to date, elucidating with statistical confidence the recurrent point mutations and copy number alterations associated with the disease. In particular, the integration of copy number and mutation analysis led to the identification of genes whose recurrent mutation is also accompanied by loss of heterozygosity (LOH), a hallmark of loss-of-function of tumor suppressor genes. On the basis of these methods, biologically important driver genes may be prioritized, even though they occur at a low frequency. Also of interest were mutations in *EGR1* (seen in seven of 203 patients). The 5' bias of the mutations and their occurring within a WRCY motif all suggest that they occur as a result of somatic hypermutation as a consequence of AID activity that is most commonly associated with the normal process of immunoglobulin gene rearrangement in B cells (Lenz and Staudt, 2010). We recently reported in the B cell malignancy DLBCL that somatic hypermutation of the *BCL2* gene occurred as a result of chromosomal translocations that bring the immunoglobulin heavy chain enhancer in proximity to the *BCL2* locus (Lohr et al., 2012). Similarly, somatic hypermutation may occur when genes are dysregulated by IGH translocations in MM. For example, we identified 39 coding and noncoding mutations in the *CCND1* locus, with some samples harboring multiple mutations. In at least four of these patients, t(11;14) translocations were also detected, suggesting the possibility that these mutations might also result from somatic hypermutation.

Interestingly, several genes, while not reaching statistical significance on their own, were part of frequently mutated pathways or processes that have been causally implicated in MM (including the NF- κ B pathway, chromatin-modifying enzymes, and RNA-processing molecules). Mutations in the RNA-binding proteins *DIS3* and *FAM46C* were collectively observed in 21% of patients. It remains unknown why these mutations occur at such high frequency in MM and yet are seen only rarely, if ever, in other types of cancer. *DIS3* mutations were often accompanied by LOH and were most commonly seen in nonhyperdiploid MM.

Additionally, we observed an accumulation of mutations in components of the cell-cycle machinery, as well as in members of the MAPK pathway. A key opportunity for the future will be to relate these mutations to the promising preclinical and clinical results that have recently been reported in MM using cyclin-dependent kinase inhibitors and RAF kinase inhibitors (Andrulis et al., 2013; Cirstea et al., 2013).

Perhaps the most striking finding of our study was that MM tumors are highly heterogeneous. Lower-resolution genetic analyses (e.g., cytogenetics, FISH, and array CGH) have pointed to the existence of clonal heterogeneity in MM, and recent studies using exome sequencing and copy number analyses in a small number of samples similarly documented clonal diversity (Egan et al., 2012; Keats et al., 2012; Walker et al., 2012). The present study of 203 patients is unprecedented in its comprehensiveness, and the analytical approach allowed us to (1) identify subclonal mutations, (2) estimate the cancer cell fraction in which these mutations occur, and (3) estimate the minimum number of subclones. Our method is statistically powered to detect subclones representing at least 10% of the overall tumor sample. It is therefore likely that our finding that MM tumor samples contain on average at least five subclones underestimates the clonal diversity of the disease. It is conceivable that a much larger number of additional subclones may also exist, either below our detection sensitivity or in nonsampled MM tissues. More comprehensive characterization of MM tissue will likely be required to resolve these questions.

Interestingly, point mutations in the most significantly mutated genes were found to be clonal in some patients but subclonal in others. That is, these mutated genes appear to be able to function both as initiators of MM and also as potentiators of the disease. For example, *BRAF* mutations were often subclonal and, in some cases, coexistent with *NRAS* or *KRAS* mutations. In our cohort, these mutations did not co-occur clonally. Rather, at least one of them was always subclonal. With increasing numbers of samples and greater depth of sequencing, many more such cases, including many different genes, may be identified. Other examples of such evolution in cancer have been reported (Campbell et al., 2010; Ding et al., 2012; Gerlinger et al., 2012; Jovanovic et al., 2010; Nik-Zainal et al., 2012; Shah et al., 2012; Walter et al., 2012; Wilmott et al., 2012).

These results also have important clinical implications for MM clinical trials. For example, *BRAF* inhibitors are being explored in MM harboring a *BRAF* mutation, and the first patient with *BRAF* V600E-positive MM who experienced a durable response to *BRAF* inhibition has just been reported (Andrulis et al., 2013). However, if a *BRAF* mutation is not clonal, suboptimal clinical benefit would be expected. In principle, treating patients harboring subclonal *BRAF* mutations with *BRAF* inhibitors may stimulate the growth of *BRAF*-wild-type tumor cells. Combined *BRAF* and MEK inhibition might mitigate this effect, but this remains to be demonstrated in vivo.

The clonal heterogeneity observed in this study offers a generally sobering view of prospects for predicting the effects of targeted therapy for cancer in general. Therapy targeting a mutation present in only a fraction of tumor cells would be expected to affect only that subclone, leading to limited clinical benefit. At worst, targeted therapy might have a paradoxically stimulatory effect on the subclones lacking the relevant mutation. At a minimum, we suggest that it will not be sufficient to simply document the presence or absence of mutations in the diagnostic setting. Rather, it will be important to enumerate the extent of clonal heterogeneity in patients being evaluated for targeted therapy and to interpret the results of subsequent therapy in light of such genetic heterogeneity. Effective targeted therapy will require either drug combinations targeting distinct subclones or, more

likely, deployment of targeted therapies only in patients for whom the drug target is entirely clonal.

EXPERIMENTAL PROCEDURES

Sample Selection and Quality Assessment of DNA

Bone marrow aspirates and peripheral blood samples were collected at Multiple Myeloma Research Consortium (MMRC) institutions from patients diagnosed with MM or related diseases and then shipped to the MMRC Tissue Bank for processing as previously described (Ahmann et al., 2008). The studies were approved by the Committee on the Use of Humans as Experimental Subjects of MIT, protocol no. 0803002647. All patients provided written informed consent under institutional review board approval. Sample processing was slightly modified from previous reports (Salhia et al., 2010) as described in the Supplemental Experimental Procedures.

Whole-Exome Sequencing, Whole-Genome Sequencing, and Detection of Copy Number Variations

Whole-exome capture libraries were constructed from 100 ng of tumor and normal DNA after shearing, end repair, phosphorylation, and ligation to bar-coded sequencing adapters (Fisher et al., 2011; Gnirke et al., 2009). Ligated DNA was size-selected for lengths between 200 and 350 bp and subjected to exonic hybrid capture using SureSelect v2 Exome bait (Agilent). Samples were multiplexed and sequenced on multiple Illumina HiSeq flow cells (paired-end 76 bp reads) to an average depth of coverage of 89× and 88× for tumor and normal, respectively. For whole-genome sequencing, library construction was done with 1–3 µg of native DNA from primary tumor and germline samples for each patient. The DNA was sheared to a range of 101–700 bp using the Covaris E210 Instrument and was then phosphorylated and adenylated according to the Illumina protocol. Adaptor ligated purification was done by preparatory gel electrophoresis, and size was selected by excision of two bands (500–520 bp and 520–540 bp, respectively), yielding two libraries per sample with average of 380 bp and 400 bp, respectively. The libraries were then sequenced with the Illumina GA-II or Illumina HiSeq sequencer with 76 or 101 bp reads, achieving an average of ~30× coverage depth. The resulting data were analyzed with the current Illumina pipeline, which generates data files (BAM files) that contain the reads and quality parameters. Copy number variations of 153 patients of the sequencing cohort were determined by Affymetrix SNP 6.0 array. Sequencing data are available in the dbGaP database (<http://www.ncbi.nlm.nih.gov/gap>) under accession number phs000348.

Analysis of Whole-Genome and Whole-Exome Sequencing Data

For a detailed description, see the Supplemental Experimental Procedures.

Myeloma Cell Lines, MM Cell Proliferation, and BRAF Inhibition

A human-derived *BRAF*-mutant cell line (U266) and three *BRAF*-wild-type cell lines (OPM2, MM1S, and SKMM1) were plated at 1.0×10^6 cells/ml (total 2.0×10^6 in 2 ml) in 6-well plates. For western blotting, cells were then treated with concentrations of 0 µM, 2.5 µM, or 10 µM *BRAF* inhibitor PLX4720 for 1 hr or 24 hr. After treatment, cells were harvested and lysed on ice for 5 min with 300 µl of a modified NP40 lysis buffer (1% NP-40, 50 mM Tris [pH 7.5], 150 mM NaCl, 2 mM EDTA [pH 8], 1 mg/ml NaF, and deuterium depleted water) for western blot analysis. For determination of the proliferation of MM cell lines in the presence of the *BRAF* inhibitor dabrafenib and the MEK inhibitor trametinib, 3,000 cells per well were plated in quadruplicate in a 384-well plate in the presence of the indicated drug concentrations.

Western Blot Analysis of MAPK Pathway after PLX4720 Treatment

Lysate protein concentrations were obtained using the BIO-RAD DC Protein Assay kit, and concentrations were subsequently adjusted to 1 µg/µl final concentrations. Twelve micrograms of protein from each cell lysate was run per well on NuPAGE 4%–12% Bis-Tris Midi Gels (Life Technologies WG1403BX10). The gel was blotted onto nitrocellulose membrane paper (Invitrogen LC2001) using the iBlot gel transfer device (Life Technologies IB1001). The membrane was subsequently blocked (Li-Cor Blocking Buffer

927–40000) for 1 hr and stained as described in the Supplemental Experimental Procedures.

ACCESSION NUMBERS

Sequencing data are available in the dbGaP database (<http://www.ncbi.nlm.nih.gov/gap>) under accession number phs000348.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, three figures, and nine tables and can be found with this article online at <http://dx.doi.org/10.1016/j.ccr.2013.12.015>.

CONSORTIA

The investigators of the Multiple Myeloma Research Consortium are Kenneth C. Anderson, Paul Richardson, Amrita Krishnan, Sagar Lonial, Jonathan Kaufman, David S. Siegel, David H. Vesole, Vivek Roy, Candido E. Rivera, S. Vincent Rajkumar, Shaji Kumar, Rafael Fonseca, Greg J. Ahmann, P. Leif Bergsagel, A. Keith Stewart, Craig C. Hofmeister, Yvonne A. Efebera, Sundar Jagannath, Ajai Chari, Suzanne Trudel, Donna Reece, Jeffrey Wolf, Thomas Martin, Todd Zimmerman, Cara Rosenbaum, Andrzej J. Jakubowiak, Daniel Lebovic, Ravi Vij, and Keith Stockerl-Goldstein.

AUTHOR CONTRIBUTIONS

J.G.L. designed and performed experiments and analyzed the data. P.S. and S.L.C. conceived and implemented computational methods for data analysis. J.G., G.S., K.C., A.M., S.E.S., M.R., and M.S.L. provided analytical support. J.G.L., S.L.C., P.S., G.G., and T.R.G. wrote the manuscript. P.C.G. performed experiments and analyzed data. D.A. and C.S. performed sample and data management and gave conceptual advice. B.K. designed experiments and analyzed data. M.A.C. and R.S. designed experiments. J.L., L.M.P. performed analysis of clinical data. J.J.K. performed sequencing analysis. The Multiple Myeloma Research Consortium contributed patient samples. G.G. and T.R.G. designed the experimental strategy and supervised the analysis. All authors discussed the results and implications and reviewed the manuscript.

ACKNOWLEDGMENTS

This project was funded by a grant from the Multiple Myeloma Research Foundation. This work was also supported by NIH grant 5P50CA100707-09 (DF/HCC SPORE in Multiple Myeloma) and a Conquer Cancer Foundation Young Investigator Award (J.G.L.). We are grateful to members of the Broad Institute's Genomics Platform, without whom this work would not have been possible, and to Jadwiga Grabarek and the members of the Golub lab for helpful discussions and critical review of the manuscript.

Received: March 3, 2013

Revised: October 9, 2013

Accepted: December 23, 2013

Published: January 13, 2014

REFERENCES

- Ahmann, G.J., Chng, W.J., Henderson, K.J., Price-Troska, T.L., DeGoe, R.W., Timm, M.M., Dispenzieri, A., Greipp, P.R., Sable-Hunt, A., Bergsagel, L., and Fonseca, R. (2008). Effect of tissue shipping on plasma cell isolation, viability, and RNA integrity in the context of a centralized good laboratory practice-certified tissue banking facility. *Cancer Epidemiol. Biomarkers Prev.* 17, 666–673.
- Andrulis, M., Lehnert, N., Capper, D., Penzel, R., Heining, C., Huellein, J., Zenz, T., von Deimling, A., Schirmacher, P., Ho, A.D., et al. (2013). Targeting the *BRAF* V600E mutation in multiple myeloma. *Cancer Discov.* 3, 862–869.

- Annunziata, C.M., Davis, R.E., Demchenko, Y., Bellamy, W., Gabrea, A., Zhan, F., Lenz, G., Hanamura, I., Wright, G., Xiao, W., et al. (2007). Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. *Cancer Cell* 12, 115–130.
- Annunziata, C.M., Hernandez, L., Davis, R.E., Zingone, A., Lamy, L., Lam, L.T., Hurt, E.M., Shaffer, A.L., Kuehl, W.M., and Staudt, L.M. (2011). A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. *Blood* 117, 2396–2404.
- Beroukhi, R., Getz, G., Nghiemphu, L., Barretina, J., Hsueh, T., Linhart, D., Vivanco, I., Lee, J.C., Huang, J.H., Alexander, S., et al. (2007). Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. *Proc. Natl. Acad. Sci. USA* 104, 20007–20012.
- Campbell, P.J., Yachida, S., Mudie, L.J., Stephens, P.J., Pleasance, E.D., Stebbings, L.A., Morsberger, L.A., Latimer, C., McLaren, S., Lin, M.L., et al. (2010). The patterns and dynamics of genomic instability in metastatic pancreatic cancer. *Nature* 467, 1109–1113.
- Cancer Genome Atlas Research Network (2011). Integrated genomic analyses of ovarian carcinoma. *Nature* 474, 609–615.
- Carter, S.L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P.W., Onofrio, R.C., Winckler, W., Weir, B.A., et al. (2012). Absolute quantification of somatic DNA alterations in human cancer. *Nat. Biotechnol.* 30, 413–421.
- Chapman, M.A., Lawrence, M.S., Keats, J.J., Cibulskis, K., Sougnez, C., Schinzel, A.C., Harview, C.L., Brunet, J.P., Ahmann, G.J., Adli, M., et al. (2011). Initial genome sequencing and analysis of multiple myeloma. *Nature* 471, 467–472.
- Chen, L., Wang, S., Zhou, Y., Wu, X., Entin, I., Epstein, J., Yaccoby, S., Xiong, W., Barlogie, B., Shaughnessy, J.D., Jr., and Zhan, F. (2010). Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma. *Blood* 115, 61–70.
- Cirstea, D., Hideshima, T., Santo, L., Eda, H., Mishima, Y., Nemani, N., Hu, Y., Mimura, N., Cottini, F., Gorgun, G., et al. (2013). Small-molecule multi-targeted kinase inhibitor BGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. *Leukemia* 27, 2366–2375.
- Comino-Méndez, I., Gracia-Aznárez, F.J., Schiavi, F., Landa, I., Leandro-García, L.J., Letón, R., Honrado, E., Ramos-Medina, R., Caronia, D., Pita, G., et al. (2011). Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. *Nat. Genet.* 43, 663–667.
- D'Costa, K., Emslie, D., Metcalf, D., Smyth, G.K., Karnowski, A., Kallies, A., Nutt, S.L., and Corcoran, L.M. (2009). Blimp1 is limiting for transformation in a mouse plasmacytoma model. *Blood* 113, 5911–5919.
- Dahlman, K.B., Xia, J., Hutchinson, K., Ng, C., Hucks, D., Jia, P., Atefi, M., Su, Z., Branch, S., Lyle, P.L., et al. (2012). BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. *Cancer Discov.* 2, 791–797.
- Demchenko, Y.N., Glebov, O.K., Zingone, A., Keats, J.J., Bergsagel, P.L., and Kuehl, W.M. (2010). Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. *Blood* 115, 3541–3552.
- Di Bernardo, M.C., Crowther-Swanepoel, D., Broderick, P., Webb, E., Sellick, G., Wild, R., Sullivan, K., Vijayakrishnan, J., Wang, Y., Pittman, A.M., et al. (2008). A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. *Nat. Genet.* 40, 1204–1210.
- Ding, L., Ley, T.J., Larson, D.E., Miller, C.A., Koboldt, D.C., Welch, J.S., Ritchey, J.K., Young, M.A., Lamprecht, T., McLellan, M.D., et al. (2012). Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. *Nature* 481, 506–510.
- Egan, J.B., Shi, C.X., Tembe, W., Christoforides, A., Kurdoglu, A., Sinari, S., Middha, S., Asmann, Y., Schmidt, J., Braggio, E., et al. (2012). Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. *Blood* 120, 1060–1066.
- Fisher, S., Barry, A., Abreu, J., Minie, B., Nolan, J., Delorey, T.M., Young, G., Fennell, T.J., Allen, A., Ambrogio, L., et al. (2011). A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. *Genome Biol.* 12, R1.
- Flaherty, K.T., Infante, J.R., Daud, A., Gonzalez, R., Keefe, R.F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. *N. Engl. J. Med.* 367, 1694–1703.
- Fonseca, R., Bergsagel, P.L., Drach, J., Shaughnessy, J., Gutierrez, N., Stewart, A.K., Morgan, G., Van Ness, B., Chesi, M., Minvielle, S., et al.; International Myeloma Working Group (2009). International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. *Leukemia* 23, 2210–2221.
- Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *N. Engl. J. Med.* 366, 883–892.
- Gnirke, A., Melnikov, A., Maguire, J., Rogov, P., LeProust, E.M., Brockman, W., Fennell, T., Giannoukos, G., Fisher, S., Russ, C., et al. (2009). Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. *Nat. Biotechnol.* 27, 182–189.
- Holien, T., Vatsveen, T.K., Hella, H., Waage, A., and Sundan, A. (2012). Addition to c-MYC in multiple myeloma. *Blood* 120, 2450–2453.
- Jovanovic, B., Egyhazi, S., Eskandarpour, M., Ghiorzo, P., Palmer, J.M., Bianchi Scarrà, G., Hayward, N.K., and Hansson, J. (2010). Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations. *J. Invest. Dermatol.* 130, 618–620.
- Kamada, Y., Sakata-Yanagimoto, M., Sanada, M., Sato-Otsubo, A., Enami, T., Suzukawa, K., Kurita, N., Nishikii, H., Yokoyama, Y., Okoshi, Y., et al. (2012). Identification of unbalanced genome copy number abnormalities in patients with multiple myeloma by single-nucleotide polymorphism genotyping microarray analysis. *Int. J. Hematol.* 96, 492–500.
- Keats, J.J., Fonseca, R., Chesi, M., Schop, R., Baker, A., Chng, W.J., Van Wier, S., Tiedemann, R., Shi, C.X., Sebag, M., et al. (2007). Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. *Cancer Cell* 12, 131–144.
- Keats, J.J., Chesi, M., Egan, J.B., Garbitt, V.M., Palmer, S.E., Braggio, E., Van Wier, S., Blackburn, P.R., Baker, A.S., Dispenzieri, A., et al. (2012). Clonal competition with alternating dominance in multiple myeloma. *Blood* 120, 1067–1076.
- Landau, D.A., Carter, S.L., Getz, G., and Wu, C.J. (2013a). Clonal evolution in hematological malignancies and therapeutic implications. *Leukemia*. Published online August 27, 2013. <http://dx.doi.org/10.1038/leu.2013.248>.
- Landau, D.A., Carter, S.L., Stojanov, P., McKenna, A., Stevenson, K., Lawrence, M.S., Sougnez, C., Stewart, C., Sivachenko, A., Wang, L., et al. (2013b). Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. *Cell* 152, 714–726.
- Lawrence, M.S., Stojanov, P., Polak, P., Kryukov, G.V., Cibulskis, K., Sivachenko, A., Carter, S.L., Stewart, C., Mermel, C.H., Roberts, S.A., et al. (2013). Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature* 499, 214–218.
- Lenz, G., and Staudt, L.M. (2010). Aggressive lymphomas. *N. Engl. J. Med.* 362, 1417–1429.
- Lin, F.R., Kuo, H.K., Ying, H.Y., Yang, F.H., and Lin, K.I. (2007). Induction of apoptosis in plasma cells by B lymphocyte-induced maturation protein-1 knockdown. *Cancer Res.* 67, 11914–11923.
- Lohr, J.G., Stojanov, P., Lawrence, M.S., Auclair, D., Chapuy, B., Sougnez, C., Cruz-Gordillo, P., Knoechel, B., Asmann, Y.W., Slager, S.L., et al. (2012). Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. *Proc. Natl. Acad. Sci. USA* 109, 3879–3884.
- Mahindra, A., Laubach, J., Raje, N., Munshi, N., Richardson, P.G., and Anderson, K. (2012). Latest advances and current challenges in the treatment of multiple myeloma. *Nat. Rev. Clin. Oncol.* 9, 135–143.
- Mandelbaum, J., Bhagat, G., Tang, H., Mo, T., Brahmachary, M., Shen, Q., Chadburn, A., Rajewsky, K., Tarakhovskiy, A., Pasqualucci, L., and Dalla-

- Favera, R. (2010). BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. *Cancer Cell* 18, 568–579.
- Mermel, C.H., Schumacher, S.E., Hill, B., Meyerson, M.L., Beroukhi, R., and Getz, G. (2011). GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. *Genome Biol.* 12, R41.
- Morin, R.D., Mendez-Lago, M., Mungall, A.J., Goya, R., Mungall, K.L., Corbett, R.D., Johnson, N.A., Severson, T.M., Chiu, R., Field, M., et al. (2011). Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. *Nature* 476, 298–303.
- Nik-Zainal, S., Van Loo, P., Wedge, D.C., Alexandrov, L.B., Greenman, C.D., Lau, K.W., Raine, K., Jones, D., Marshall, J., Ramakrishna, M., et al.; Breast Cancer Working Group of the International Cancer Genome Consortium (2012). The life history of 21 breast cancers. *Cell* 149, 994–1007.
- Palumbo, A., and Anderson, K. (2011). Multiple myeloma. *N. Engl. J. Med.* 364, 1046–1060.
- Pasqualucci, L., Neumeister, P., Goossens, T., Nanjangud, G., Chaganti, R.S., Küppers, R., and Dalla-Favera, R. (2001). Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. *Nature* 412, 341–346.
- Poulikakos, P.I., Zhang, C., Bollag, G., Shokat, K.M., and Rosen, N. (2010). RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. *Nature* 464, 427–430.
- Salhia, B., Baker, A., Ahmann, G., Auclair, D., Fonseca, R., and Carpten, J. (2010). DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors. *Cancer Res.* 70, 6934–6944.
- Shaffer, A.L., Emre, N.C., Lamy, L., Ngo, V.N., Wright, G., Xiao, W., Powell, J., Dave, S., Yu, X., Zhao, H., et al. (2008). IRF4 addiction in multiple myeloma. *Nature* 454, 226–231.
- Shah, S.P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012). The clonal and mutational evolution spectrum of primary triple-negative breast cancers. *Nature* 486, 395–399.
- Shou, Y., Martelli, M.L., Gabrea, A., Qi, Y., Brents, L.A., Roschke, A., Dewald, G., Kirsch, I.R., Bergsagel, P.L., and Kuehl, W.M. (2000). Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. *Proc. Natl. Acad. Sci. USA* 97, 228–233.
- Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and Mesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. USA* 102, 15545–15550.
- Tai, Y.T., Fulciniti, M., Hideshima, T., Song, W., Leiba, M., Li, X.F., Rumizen, M., Burger, P., Morrison, A., Podar, K., et al. (2007). Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. *Blood* 110, 1656–1663.
- Walker, B.A., Wardell, C.P., Melchor, L., Hulkki, S., Potter, N.E., Johnson, D.C., Fenwick, K., Kozarewa, I., Gonzalez, D., Lord, C.J., et al. (2012). Intracлонаl heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. *Blood* 120, 1077–1086.
- Walter, M.J., Shen, D., Ding, L., Shao, J., Koboldt, D.C., Chen, K., Larson, D.E., McLellan, M.D., Dooling, D., Abbott, R., et al. (2012). Clonal architecture of secondary acute myeloid leukemia. *N. Engl. J. Med.* 366, 1090–1098.
- Wilmott, J.S., Tembe, V., Howle, J.R., Sharma, R., Thompson, J.F., Rizos, H., Lo, R.S., Kefford, R.F., Scolyer, R.A., and Long, G.V. (2012). Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. *Mol. Cancer Ther.* 11, 2704–2708.